Unicycive Therapeutics (NASDAQ:UNCY) Given Buy Rating at HC Wainwright

Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report)'s stock had its "buy" rating reissued by research analysts at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They presently have a $2.50 price target on the stock. HC Wainwright's target price points to a potential upside of 416.10% from the stock's current price.

Separately, Benchmark reaffirmed a "speculative buy" rating and set a $3.00 price target on shares of Unicycive Therapeutics in a research note on Friday, September 6th. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $5.13.

Unicycive Therapeutics Stock Performance

Shares of Unicycive Therapeutics stock traded down $0.05 on Tuesday, hitting $0.48. 3,051,052 shares of the company's stock were exchanged, compared to its average volume of 1,218,576. The stock has a market capitalization of $45.71 million, a PE ratio of -0.51 and a beta of 2.29. The company has a 50-day simple moving average of $0.42 and a 200-day simple moving average of $0.56. Unicycive Therapeutics has a 1 year low of $0.20 and a 1 year high of $1.82.

Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($0.15) earnings per share for the quarter, topping analysts' consensus estimates of ($0.23) by $0.08. On average, analysts expect that Unicycive Therapeutics will post -0.26 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. BVF Inc. IL boosted its position in shares of Unicycive Therapeutics by 70.5% during the 1st quarter. BVF Inc. IL now owns 3,611,601 shares of the company's stock worth $4,984,000 after purchasing an additional 1,493,462 shares during the period. Bleakley Financial Group LLC acquired a new position in Unicycive Therapeutics during the third quarter worth approximately $33,000. Finally, Virtu Financial LLC purchased a new stake in Unicycive Therapeutics during the first quarter worth approximately $36,000. Hedge funds and other institutional investors own 40.42% of the company's stock.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.